Barbarash R A, Bauman J L, Lukazewski A A, Srebro J P, Rich S
Crit Care Med. 1986 Oct;14(10):886-8. doi: 10.1097/00003246-198610000-00011.
Ten patients with symptomatic atrial tachyarrhythmias were treated with an iv verapamil bolus (mean 8.5 mg) followed by a continuous verapamil infusion (mean dose 9.4 mg/h). The infusions were titrated to ventricular rate and continued for an average of 20 h, until oral therapy could be instituted. All patients had a significant, sustained reduction in ventricular rate during the infusion, without a significant reduction in mean arterial pressure. Although one patient complained of dizziness after 8 h of infusion therapy, the regimen was generally well tolerated and no patient had clinical worsening of heart failure. These preliminary data suggest that continuous verapamil infusions can safely and effectively control ventricular rate in patients with rapid atrial tachyarrhythmias, until oral medications can be started.
10例有症状性房性快速心律失常患者接受静脉注射维拉帕米推注(平均8.5毫克),随后持续静脉输注维拉帕米(平均剂量9.4毫克/小时)。输注量根据心室率进行调整,平均持续20小时,直至可以开始口服治疗。所有患者在输注期间心室率均有显著、持续下降,平均动脉压无显著降低。虽然1例患者在输注治疗8小时后诉头晕,但该方案总体耐受性良好,无患者出现心力衰竭临床恶化。这些初步数据表明,在开始口服药物治疗前,持续静脉输注维拉帕米可安全有效地控制快速房性快速心律失常患者的心室率。